3,4-O-异亚丙基-L-苏糖酸甲酯 | 92973-40-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3,4-O-异亚丙基-L-苏糖酸甲酯
• 中文别名: 3,4-O-异丙叉-L-苏酮酸甲酯；3,4-O-异亚丙基-L-苏酮酸甲酯
• 英文名称: methyl (2R,3S)-3,4-O-isopropylidene-2,3,4-trihydroxybutanoate
• 英文别名: methyl 3,4-O-isopropylidene-L-threonate；methyl (R)-2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-hydroxyacetate；(2R)-2-((4S)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-hydroxyacetic acid methyl ester；(R)-methyl 2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-hydroxyacetate；methyl (2R)-2-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]-2-hydroxyacetate
• CAS: 92973-40-5
• 化学式: C₈H₁₄O₅
• 分子量: 190.196
• InChiKey: JSFASCPVVJBLRD-NTSWFWBYSA-N

物化性质

• 沸点：
  125 °C12 mm Hg(lit.)
• 密度：
  1.175 g/mL at 25 °C(lit.)
• 闪点：
  210 °F
• 稳定性/保质期：

  在常温常压下稳定，避免接触强氧化剂。

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  65
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 安全说明：
  S23,S24/25
• 海关编码：
  2932999099
• WGK Germany：
  3
• 储存条件：
  请将贮藏器密封，并放入一个紧密封装的容器中。储存时应选择阴凉、干燥的地方。

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : Methyl 3,4-O-isopropylidene-L-threonate
CAS-No. : 92973-40-5
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
The product does not need to be labelled in accordance with EC directives or respective national laws.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
: (αR,4S)-2,2-Dimethyl-α-hydroxy-1,3-dioxolane-4-acetic acid methyl ester
Synonyms
3,4-O-Isopropylidene-L-threonic acid methyl ester
Formula : C8H14O5
Molecular Weight : 190,19 g/mol

---

Section 4. FIRST AID MEASURES
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Avoid breathing vapors, mist or gas.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Normal measures for preventive fire protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place. Containers which are
opened must be carefully resealed and kept upright to prevent leakage.
Specific end use(s)
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Impervious clothing., The type of protective equipment must be selected according to the
concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection not required. For nuisance exposures use type OV/AG (US) or type ABEK
(EU EN 14387) respirator cartridges. Use respirators and components tested and approved under
appropriate government standards such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: clear, viscous liquid
Colour: light yellow
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and 125 °C at 16 hPa - lit.
boiling range
g) Flash point 99 °C - closed cup
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density 1,175 g/cm3 at 25 °C
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes May cause eye irritation.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine Pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3,4-O-异亚丙基-L-苏糖酸甲酯 在 吡啶 、 lithium aluminium tetrahydride 、 偶氮二异丁腈 、 三正丁基氢锡 作用下， 以 四氢呋喃 、 二氯甲烷 、 甲苯 为溶剂， 反应 6.83h， 生成 (R)-4-(2-羟乙基)-2,2-二甲基-1,3-二氧戊环
  参考文献：
  名称：

  Preparation of Derivtives of (R)-1,2,4-Butanetriol from L-Ascorbic Acid

  摘要：

  从 L-抗坏血酸中得到的 3,4-O-异亚丙基 L-苏氨酸甲酯（3）被转化为其 O-苯基硫代碳酸酯 4。用氢化三正丁基锡对 4 进行脱氧反应，得到受保护的 3,4-二羟基丁酸酯 5，再将其转化为 (R)-1,2,4-丁三醇衍生物 6 和 7。

  DOI：

  10.1055/s-1988-27521
• 作为产物：
  描述：

  5,6-O-isopropylidene-L-ascorbic acid 在 碳酸氢钠 、 sodium hydroxide 、 sodium sulfite 作用下， 以 水 为溶剂， 反应 6.0h， 生成 3,4-O-异亚丙基-L-苏糖酸甲酯
  参考文献：
  名称：

  尼古丁的合成研究：侧链的合成及其酯化

  摘要：

  尼古丁是一种杀菌剂倍半萜内酯，对原虫寄生虫布鲁氏锥虫具有有效的抑制作用，布鲁氏锥虫引起人类非洲锥虫病（HAT）。尽管尼古丁具有令人感兴趣的结构和有吸引力的生物学活性，但尚未报道尼古丁的合成研究。本报告描述在cnicin的C8保护侧链的羧酸结构部分的合成通过从开始两条路线升抗坏血酸。此外，合成侧链和红红血lide内酯衍生物之间的酯化反应可以通过烟碱的水解和伯醇的保护来实现。因此，实现了尼古丁的半合成。

  DOI：

  10.1016/j.tetlet.2016.11.067

文献信息

• [EN] PROCESS FOR THE PREPARATION OF [(1 S,2R)-3-[[(4-AMINOPHENYL)SULFONYL] (2-METHYLPROPYL)AMINO]-2-HYDROXY-1 -(PHENYLMETHYL)PROPYL]-CARBAMIC ACID (3R,3AS,6AR)HEXAHYDRO FURO[2,3-B]FURAN-3-YL ESTER AND ITS AMORPHOUS FORM<br/>[FR] PROCÉDÉ DE PRÉPARATION DE (3R,3AS,6AR)HEXAHYDROFURO[2,3-B]FURAN-3-YL ESTER D'ACIDE [(1S,2R)-3-[[(4-AMINOPHÉNYL) SULFONYL](2-MÉTHYLPROPYL)AMINO]-2-HYDROXY-1-(PHÉNYLMÉTHYL)PROPYL]-CARBAMIQUE ET SA FORME AMORPHE
  申请人：MSN LABORATORIES PRIVATE LTD

  公开号：WO2016207907A1

  公开（公告）日：2016-12-29

  The present invention relates to an improved process for the preparation of [(1 S,2R)-3-[ [(4-aminophenyl)sulfonyl] (2-methylpropyl)amino]-2-hydroxy- 1 -(phenylmethyl)propyl] - carbamic acid (3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-yl ester compound of formula- 1 represented by the following structural formula:

  本发明涉及一种改进的制备过程，用于制备以下结构式表示的化合物的酯：[(1 S,2R)-3-[ [(4-aminophenyl)sulfonyl] (2-methylpropyl)amino]-2-hydroxy- 1 -(phenylmethyl)propyl] - carbamic acid (3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-yl。
• Solid-phase library synthesis of reversed-statine type inhibitors of the malarial aspartyl proteases plasmepsin I and II
  作者：Anders Dahlgren、Ingemar Kvarnström、Lotta Vrang、Elizabeth Hamelink、Anders Hallberg、Åsa Rosenquist、Bertil Samuelsson

  DOI：10.1016/s0968-0896(02)00568-0

  日期：2003.3

  With the aim to develop inhibitors of the plasmepsin I and II aspartic proteases of the malaria parasite Plasmodium falciparum, we have synthesized sets of libraries from novel reversed-statine isosteres, using a combination of solution phase and solid phase chemistry. The synthetic strategy furnishes the library compounds in good to high overall yields and with excellent stereochemical control throughout

  为了开发疟原虫恶性疟原虫的纤溶酶I和II天冬氨酸蛋白酶的抑制剂，我们使用溶液相和固相化学相结合的方法，从新型逆状态他汀类固醇合成了许多文库。合成策略使文库化合物具有良好或较高的总收率，并且在整个开发过程中均具有出色的立体化学控制。对产物的纤溶酶I和II抑制特性进行了评估，发现它们具有适度但有希望的活性。最好的抑制剂在0.5 microM的抑制剂浓度下（对Plm II的K（i）= 5.4 microM）表现出28％的纤溶酶II抑制作用。
• ピラゾール誘導体の製造方法
  申请人：キッセイ薬品工業株式会社

  公开号：JP2018108988A

  公开（公告）日：2018-07-12

  【課題】ピラゾール誘導体の製造方法の提供。【解決手段】式（IIC）、（IID）または（III）で表される化合物と、式（IV）で表される化合物を用いるピラゾール誘導体の製造方法。【選択図】なし

  提供制备嘧啶衍生物的方法。使用式（IIC）、（IID）或（III）表示的化合物和使用式（IV）表示的化合物制备嘧啶衍生物的方法。不包括图。
• Intramolecular 1,3-Dipolar Cycloaddition of Transient Enantiomerically Pure Oxaalkenyl Nitrones
  作者：Hans Günter Aurich、Frank Biesemeier

  DOI：10.1055/s-1995-4060

  日期：1995.9

  A variety of enantiomerically pure α-hydroxy esters were converted into enantiomerically pure 3,7-dioxa-2-azabicyclo[3.3.0]octanes 7 by the following reaction sequence. Allylation of the hydroxy group was followed by reduction of the ester group. The resulting aldehyde was treated with an N-alkylhydroxylamine to give an oxaalkenyl nitrone 6 which underwent spontaneously an intramolecular 1,3-dipolar cycloaddition affording 7. Opening of the isoxazolidine ring of 7 by various reductive methods yielded the highly substituted tetrahydrofuran derivatives 11.

  多种手性纯的α-羟基酯通过以下反应序列转化为手性纯的3,7-二氧杂-2-氮杂双环[3.3.0]辛烷7。首先是羟基的烯丙基化，随后酯官能团被还原。生成的醛与N-烷基羟胺反应得到氧杂烯基硝酮6，该硝酮自发进行1,3-偶极环加成反应生成产物7。通过多种还原方法解开产物7中的异恶唑啉环，得到高度取代的四氢呋喃衍生物11。
• [EN] N- (6- ( (2R,3S) -3,4-DIHYDROXYBUTAN-2-YLOXY) -2- (4 - FLUOROBENZYLTHIO) PYRIMIDIN- 4 - YL) -3- METHYLAZETIDINE- 1 - SULFONAMIDE AS CHEMOKINE RECEPTOR MODULATOR<br/>[FR] N-(6-((2R,3S)-3,4-DIHYDROXYBUTAN-2-YLOXY)-2-(4-FLUOROBENZYLTHIO) PYRIMIDIN-4-YL)-3-METHYLAZETIDINE-1-SULFONAMIDE UTILISÉ EN TANT QUE MODULATEUR DU RÉCEPTEUR DE CHIMIOKINE
  申请人：ASTRAZENECA AB

  公开号：WO2013008002A1

  公开（公告）日：2013-01-17

  There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates used in the manufacture of the compound, and pharmaceutical compositions containing the compound. The compound is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.

  提供了一种化合物，该化合物是（a）式（I）的嘧啶磺胺或（b）其药用可接受盐，该化合物的晶型，获得该化合物的过程，用于制造该化合物的药用中间体，以及含有该化合物的药物组合物。该化合物在治疗需要调节趋化因子受体活性有益的疾病/症状中有用。